Literature DB >> 12584559

Role of TFG sequences outside the coiled-coil domain in TRK-T3 oncogenic activation.

Emanuela Roccato1, Sonia Pagliardini, Loredana Cleris, Silvana Canevari, Franca Formelli, Marco A Pierotti, Angela Greco.   

Abstract

The TRK-T3 oncoprotein, isolated from a human papillary thyroid tumor, arises from the fusion between the N-terminal domain of the TFG gene and the tyrosine kinase domain of the NTRK1 receptor. The 68 kDa TRK-T3 oncoprotein displays a constitutive tyrosine kinase activity resulting in its capability to transform NIH3T3 cells. The TFG portion of TRK-T3 contains a coiled-coil domain, which mediates protein oligomerization essential for the oncogene constitutive activation, and several consensus sites for protein interaction. In this study, we investigate the role of TFG sequences outside the coiled-coil domain on TRK-T3 activation, We constructed four mutants carrying different deletions of TFG sequences and expressed them in mammalian cells. By performing biochemical and biological assays we demonstrated that all the deleted regions are required for TRK-T3 activation, as they are involved in different mechanisms such as protein processing, formation of stable and/or functional complexes, and possible interaction with other proteins. By constructing site-specific mutants, we demonstrated a crucial role for a PB1 domain and a considerable contribution of an SH2-binding motif in TRK-T3 oncogenic activation. This work establishes an important role for TFG sequences outside the coiled-coil domain in the activation of the thyroid TRK-T3 oncogene.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12584559     DOI: 10.1038/sj.onc.1206189

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  The PB1 domain and the PC motif-containing region are structurally similar protein binding modules.

Authors:  Sosuke Yoshinaga; Motoyuki Kohjima; Kenji Ogura; Masashi Yokochi; Ryu Takeya; Takashi Ito; Hideki Sumimoto; Fuyuhiko Inagaki
Journal:  EMBO J       Date:  2003-10-01       Impact factor: 11.598

Review 2.  Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases.

Authors:  Vladimir N Uversky; Vrushank Davé; Lilia M Iakoucheva; Prerna Malaney; Steven J Metallo; Ravi Ramesh Pathak; Andreas C Joerger
Journal:  Chem Rev       Date:  2014-05-15       Impact factor: 60.622

3.  PB1 domain interaction of p62/sequestosome 1 and MEKK3 regulates NF-kappaB activation.

Authors:  Kazuhiro Nakamura; Adam J Kimple; David P Siderovski; Gary L Johnson
Journal:  J Biol Chem       Date:  2009-11-10       Impact factor: 5.157

4.  Intrinsic structural disorder confers cellular viability on oncogenic fusion proteins.

Authors:  Hedi Hegyi; László Buday; Peter Tompa
Journal:  PLoS Comput Biol       Date:  2009-10-30       Impact factor: 4.475

5.  ced-4 and proto-oncogene tfg-1 antagonistically regulate cell size and apoptosis in C. elegans.

Authors:  Ling Chen; Tom McCloskey; Pradeep M Joshi; Joel H Rothman
Journal:  Curr Biol       Date:  2008-07-22       Impact factor: 10.834

6.  Immunohistochemical Mapping of TRK-Fused Gene Products in the Rat Brainstem.

Authors:  Shigeko Takeuchi; Chiaki Masuda; Hisae Maebayashi; Ikuo Tooyama
Journal:  Acta Histochem Cytochem       Date:  2012-02-11       Impact factor: 1.938

7.  Expression and Localization of TRK-Fused Gene Products in the Rat Brain and Retina.

Authors:  Hisae Maebayashi; Shigako Takeuchi; Chiaki Masuda; Satoshi Makino; Kenji Fukui; Hiroshi Kimura; Ikuo Tooyama
Journal:  Acta Histochem Cytochem       Date:  2011-12-13       Impact factor: 1.938

Review 8.  Wrecked regulation of intrinsically disordered proteins in diseases: pathogenicity of deregulated regulators.

Authors:  Vladimir N Uversky
Journal:  Front Mol Biosci       Date:  2014-07-25

9.  Deep Evolutionary History of the Phox and Bem1 (PB1) Domain Across Eukaryotes.

Authors:  Sumanth Kumar Mutte; Dolf Weijers
Journal:  Sci Rep       Date:  2020-03-02       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.